{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-21-000033","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2021-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.132918+00:00","generated_at":"2026-06-27T22:38:41.790314+00:00","sec_items":["1.01","2.03","7.01","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcutis secures $225M non-dilutive debt facility; FDA accepts NDA for roflumilast cream (PDUFA July 2022)","bullets":["$75M drawn at closing; additional $125M available upon FDA approval of roflumilast cream for plaque psoriasis; $25M upon revenue milestones.","Loan maturity January 2027; interest-only period for entire five years; floating rate = 7.45% + 1M SOFR.","FDA accepted NDA for roflumilast cream (psoriasis) with PDUFA target action date of July 29, 2022.","Proceeds extend cash runway into 2024; non-dilutive financing from SLR Capital Partners.","Loan secured by substantially all assets; prepayment premiums of 3%/2%/1% declining over time."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-21-000033","json":"https://secwatch.observer/filing/0001787306-21-000033.json","markdown":"https://secwatch.observer/filing/0001787306-21-000033.md","text":"https://secwatch.observer/filing/0001787306-21-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730621000033/0001787306-21-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730621000033/arqt-20211222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T22:38:41.790314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}